Wikidata

(Q43757205)

English

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

scientific article

In more languages

Statements

title
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients (English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22431570
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22431570%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 January 2020
author
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q43757205&oldid=2120340213"